Back to discover

Protein / target

Serine/threonine-protein kinase 3

Encoded bySTK3Q13188Homo sapiensSwiss-Prot
Small-molecule tractable
Druggability
Structure with Ligand
1
Research papers

Protein at a glance

Biological role

Protein serine/threonine kinase activator

Strongest disease association

Hypotension

Via encoding gene STK3 · Genetic evidence · score 0.43

Research activity

Emerging research

1 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Stress-activated, pro-apoptotic kinase which, following caspase-cleavage, enters the nucleus and induces chromatin condensation followed by internucleosomal DNA fragmentation.

View complete UniProt function annotation

Stress-activated, pro-apoptotic kinase which, following caspase-cleavage, enters the nucleus and induces chromatin condensation followed by internucleosomal DNA fragmentation (PubMed:11278283, PubMed:8566796, PubMed:8816758). Key component of the Hippo signaling pathway which plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein STK3/MST2 and STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ (PubMed:15688006, PubMed:16930133, PubMed:23972470, PubMed:28087714, PubMed:29063833, PubMed:30622739). Phosphorylation of YAP1 by LATS2 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration (PubMed:15688006, PubMed:16930133, PubMed:23972470, PubMed:28087714). STK3/MST2 and STK4/MST1 are required to repress proliferation of mature hepatocytes, to prevent activation of facultative adult liver stem cells (oval cells), and to inhibit tumor formation. Phosphorylates NKX2-1 (By similarity). Phosphorylates NEK2 and plays a role in centrosome disjunction by regulating the localization of NEK2 to centrosome, and its ability to phosphorylate CROCC and CEP250 (PubMed:21076410, PubMed:21723128). In conjunction with SAV1, activates the transcriptional activity of ESR1 through the modulation of its phosphorylation (PubMed:21104395). Positively regulates RAF1 activation via suppression of the inhibitory phosphorylation of RAF1 on 'Ser-259' (PubMed:20212043). Phosphorylates MOBKL1A and RASSF2 (PubMed:19525978). Phosphorylates MOBKL1B on 'Thr-74'. Acts cooperatively with MOBKL1B to activate STK38 (PubMed:18328708, PubMed:18362890)

Subcellular location

CytoplasmNucleusCytoplasm, cytoskeleton, microtubule organizing center, centrosome
Domains and Gene Ontology detail (28)

Domains & features

Protein kinaseSARAH

Gene Ontology

  • Ccentrosome
  • Ccytoplasm
  • Ccytosol
  • Cnucleus
  • Cprotein-containing complex
  • FATP binding
  • Fidentical protein binding
  • Fmagnesium ion binding
  • Fprotein kinase activity
  • Fprotein serine kinase activity
  • Fprotein serine/threonine kinase activator activity
  • Fprotein serine/threonine kinase activity

491 aa · 56 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell migrationUniProtApoptosis & cell deathUniProt · GOTranscriptional regulationUniProt · GOKinase signallingGO
View supporting evidence

Cell migration

  • ·Stress-activated, pro-apoptotic kinase which, following caspase-cleavage, enters the nuc…

Apoptosis & cell death

  • ·Stress-activated, pro-apoptotic kinase which, following caspase-cleavage, enters the nuc…
  • ·apoptotic process
  • ·positive regulation of apoptotic process

Transcriptional regulation

  • ·Stress-activated, pro-apoptotic kinase which, following caspase-cleavage, enters the nuc…
  • ·transcription regulator activator activity

Kinase signalling

  • ·protein kinase activity
  • ·protein serine kinase activity
  • ·protein serine/threonine kinase activator activity
  • ·protein serine/threonine kinase activity

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene STK3

Gene-level evidence surfaced through the gene STK3that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Hypotension
0.43Limited support

Genetic evidence dominant · Open Targets 0.26

Alzheimer's Disease
0.42Limited support

Genetic evidence dominant · Open Targets 0.25

Benign prostatic hyperplasia
0.41Limited support

Genetic evidence dominant · Open Targets 0.25

Esophageal Squamous Cell Carcinoma
0.10Preliminary

Literature evidence dominant · Open Targets 0.08 · no direct causal or clinical evidence

Leukemia, Myeloid, Acute
0.10Preliminary

Literature evidence dominant · Open Targets 0.08 · no direct causal or clinical evidence

View evidence synthesis (5)
HypotensionLimited support
0.43
agreement 0.310.55
Genetic100%

Open Targets aggregate 0.26 · 1 independent evidence family

Alzheimer's DiseaseLimited support
0.42
agreement 0.280.56
Genetic94%Literature6%

Open Targets aggregate 0.25 · 2 independent evidence families

Benign prostatic hyperplasiaLimited support
0.41
agreement 0.290.53
Genetic100%

Open Targets aggregate 0.25 · 1 independent evidence family

Esophageal Squamous Cell CarcinomaPreliminary
0.10
agreement 0.000.38
Literature100%

Open Targets aggregate 0.08 · 1 independent evidence family · no direct causal or clinical evidence

Leukemia, Myeloid, AcutePreliminary
0.10
agreement 0.000.37
Literature100%

Open Targets aggregate 0.08 · 1 independent evidence family · no direct causal or clinical evidence

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Hypotension0.26
Alzheimer's Disease0.25
Benign prostatic hyperplasia0.25
Esophageal Squamous Cell Carcinoma0.08
Leukemia, Myeloid, Acute0.08
Pancreatic Neoplasms0.08
Ovarian carcinoma0.08
Ovarian Neoplasms0.08

Tractability

Small moleculesEmerging

Feasibility evidence (structure with ligand and high-quality ligand) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (uniprot ubiquitination and database ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (7)
SM · Structure with LigandSM · High-Quality LigandSM · Druggable FamilyPR · UniProt UbiquitinationPR · Database UbiquitinationPR · Half-life DataPR · Small Molecule Binder

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 2024

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Europe PMC papers linked directly to this protein.